Loading company
Celcuity Inc.
CELC · Nasdaq · ·
Next earnings: November 11, 2026
$77.30-2.9%Sep 29 close
- 1M
- -12.6%
- 6M
- -28.6%
- 1Y
- +56.5%
- 5Y
- +321.0%
CELC · Nasdaq · ·
Next earnings: November 11, 2026
$77.30-2.9%Sep 29 close
Celcuity Inc. is scheduled to report next on November 11, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Profit | -$78.9M | -$45.3M | -74.22% |
| Profit per share | -$1.44 | -$1.04 | -38.46% |
| Free Cash Flow | -$55.5M | -$36.3M | -53.04% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Celcuity Inc. has no earnings call transcript available.
“Celcuity made monumental progress these past few months, achieving critical clinical and regulatory milestones related to gedatolisib. With the FDA approval of REVTORPYK, positive results from the PIK3CA MT cohort of the pivotal VIKTORIA-1 study, and a preferred Category 1 recommendation in the NCCN Guidelines®, we are well positioned to address a significant unmet need for the tens of thousands of patients affected each year by HR+/HER2-, PIK3CAwild-type locally advanced or metastatic breast cancer whose disease has progressed after endocrine therapy,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
(gedatolisib) REVTORPYK (gedatolisib) is a kinase inhibitor indicated in combination with fulvestrant, with or without palbociclib, for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting. Please click here for Important Safety Information and Full Prescribing Information for REVTORPYK.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Celcuity Inc.’s Item 2.02 8-K filed August 13, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.